.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,647,656

« Back to Dashboard

Details for Patent: 8,647,656

Title:Orally disintegrating tablet compositions of lamotrigine
Abstract: The compositions of the present invention composition comprise a therapeutically effective amount of particles comprising lamotrigine, in combination with granules comprising a disintegrant, and a sugar alcohol and/or a saccharide. These compositions are useful in treating epilepsy and bipolar disorder, particularly for patients with dysphagia, and to improve compliance with bipolar patients.
Inventor(s): Venkatesh; Gopi M. (Vandalia, OH), Vyas; Nehal H. (Huber Heights, OH), Gosselin; Michael (Loveland, OH), Lai; Jin-Wang (Springboro, OH)
Assignee: Aptalis Pharmatech, Inc. (Vandalia, OH)
Filing Date:Dec 01, 2009
Application Number:12/628,677
Claims:1. An ODT composition consisting essentially of: a therapeutically effective amount of lamotrigine microcapsules comprising 25 or 200 mg of lamotrigine crystals having an average particle size of about 1-50 .mu.m, coated with a taste-masking layer; a disintegrant; and a sugar alcohol, a saccharide, or both a sugar alcohol and a saccharide; wherein after a single oral administration said ODT composition provides: a C.sub.max in the range of 0.276 to 0.482 ng/mL of lamotrigine, an AUC.sub.0-24 in the range of 4.87 to 8.17 nghr/mL of lamotrigine, or both a C.sub.max in the range of 0.276 to 0.482 ng/mL of lamotrigine and an AUC.sub.0-24 in the range of 4.87 to 8.17 nghr/mL of lamotrigine, if the total amount of lamotrigine in the ODT is 25 mg, or a C.sub.max in the range of 2.21 to 3.95 ng/mL of lamotrigine, an AUC.sub.0-24 in the range of 36.0 to 63.6 nghr/mL of lamotrigine, or both a C.sub.max in the range of 2.21 to 3.95 ng/mL of lamotrigine and an AUC.sub.0-24 in the range of 36.0 to 63.6 nghr/mL of lamotrigine, if the total amount of lamotrigine in the ODT is 200 mg.

2. The ODT composition of claim 1, wherein the disintegrant is selected from the group consisting of crospovidone, sodium starch glycolate, crosslinked sodium carboxymethyl cellulose, low substituted hydroxypropyl cellulose, and mixtures thereof.

3. The ODT composition of claim 1, wherein the sugar alcohol is selected from the group consisting of arabitol, isomalt, erythritol, glycerol, lactitol, mannitol, sorbitol, xylitol, maltitol, and mixtures thereof.

4. The ODT composition of claim 1, wherein the saccharide is selected from the group consisting of glucose, fructose, lactose, ribose, sucrose, maltose, trehalose, cellobiose, and mixtures thereof.

5. The ODT composition of claim 1, wherein the ODT composition consists essentially of the lamotrigine microcapsules, the disintegrant, and a sugar alcohol, wherein the sugar alcohol is selected from the group consisting of arabitol, isomalt, erythritol, glycerol, lactitol, mannitol, sorbitol, xylitol, maltitol, and mixtures thereof.

6. The ODT composition of claim 2 consisting essentially of the lamotrigine microcapsules, the disintegrant, and a sugar alcohol, wherein the sugar alcohol is selected from the group consisting of arabitol, isomalt, erythritol, glycerol, lactitol, mannitol, sorbitol, xylitol, maltitol, and mixtures thereof.

7. The ODT composition of claim 1, wherein the ODT composition consists essentially of the lamotrigine microcapsules, the disintegrant, and a saccharide, wherein the saccharide is selected from the group consisting of glucose, fructose, lactose, ribose, sucrose, maltose, trehalose, cellobiose, and mixtures thereof.

8. The ODT composition of claim 2, wherein the ODT composition consists essentially of the lamotrigine microcapsules, the disintegrant, and a saccharide, wherein the saccharide is selected from the group consisting of glucose, fructose, lactose, ribose, sucrose, maltose, trehalose, cellobiose, and mixtures thereof.

9. The ODT composition of claim 1, wherein the ODT composition substantially disintegrates within about 60 seconds after administration in the oral cavity of the patient.

10. The ODT composition of claim 9, wherein the ODT composition substantially disintegrates within about 30 seconds after administration in the oral cavity of the patient.

11. The ODT composition of claim 1, wherein the ODT composition disintegrates within about 30 seconds when tested by the <USP 701> Disintegration Test.

12. The ODT composition of claim 1, wherein the ODT composition releases about 70% or more of the total dose of lamotrigine upon entering the stomach of a patient.

13. The ODT composition of claim 1, further comprising additional pharmaceutically acceptable ingredients selected from the group consisting of a filler, a flavor, a sweetener, a colorant, and combinations thereof.

14. The ODT composition of claim 1, wherein the ODT composition provides a C.sub.max in the range of 0.276 to 0.482 ng/mL of lamotrigine, if the total amount of lamotrigine in the ODT is 25 mg.

15. The ODT composition of claim 1, wherein the ODT composition provides an AUC.sub.0-24 in the range of 4.87 to 8.17 nghr/mL of lamotrigine, if the total amount of lamotrigine in the ODT is 25 mg.

16. The ODT composition of claim 1, wherein the ODT composition provides a C.sub.max in the range of 0.276 to 0.482 ng/mL of lamotrigine and an AUC.sub.0-24 in the range of 4.87 to 8.17 nghr/mL of lamotrigine, if the total amount of lamotrigine in the ODT is 25 mg.

17. The ODT composition of claim 1, wherein the ODT composition provides a C.sub.max in the range of 2.21 to 3.95 ng/mL of lamotrigine, if the total amount of lamotrigine in the ODT is 200 mg.

18. The ODT composition of claim 1, wherein the ODT composition provides an AUC.sub.0-24 in the range of 36.0 to 63.6 nghr/mL of lamotrigine, if the total amount of lamotrigine in the ODT is 200 mg.

19. The ODT composition of claim 1, wherein the ODT composition provides a C.sub.max in the range of 2.21 to 3.95 ng/mL of lamotrigine and an AUC.sub.0-24 in the range of 36.0 to 63.6 nghr/mL of lamotrigine, if the total amount of lamotrigine in the ODT is 200 mg.

20. An ODT composition consisting essentially of: a therapeutically effective amount of lamotrigine microcapsules comprising 25 or 200 mg of lamotrigine crystals having an average particle size of about 1-50 .mu.m, coated with a taste-masking layer comprising a pharmaceutically acceptable water-insoluble polymer and a pharmaceutically acceptable water-soluble or gastro-soluble pore-former in a ratio of about 95/5 to about 50/50; a disintegrant; and a sugar alcohol, a saccharide, or both a sugar alcohol and a saccharide; wherein after a single oral administration said ODT composition provides: a C.sub.max in the range of 0.276 to 0.482 ng/mL of lamotrigine, an AUC.sub.0-24 in the range of 4.87 to 8.17 nghr/mL of lamotrigine, or both a C.sub.max in the range of 0.276 to 0.482 ng/mL of lamotrigine and an AUC.sub.0-24 in the range of 4.87 to 8.17 nghr/mL of lamotrigine, if the total amount of lamotrigine in the ODT is 25 mg, or a C.sub.max in the range of 2.21 to 3.95 ng/mL of lamotrigine, an AUC.sub.0-24 in the range of 36.0 to 63.6 nghr/mL of lamotrigine, or both a C.sub.max in the range of 2.21 to 3.95 ng/mL of lamotrigine and an AUC.sub.0-24 in the range of 36.0 to 63.6 nghr/mL of lamotrigine, if the total amount of lamotrigine in the ODT is 200 mg; and wherein the ODT composition releases about 70% or more of the total amount of lamotrigine in 30 min when tested for dissolution using United States Pharmacopeia Apparatus 2 (paddles@ 75 rpm in 900 mL of 0.01 N HCl buffer).
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc